Kissei Pharmaceutical Co., Ltd - KIS

Kissei Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in Japan. The company offers Urief tablets for the treatment of dysuria; Glufast and Glubes tablets for diabetes; Epoetin Alfa BS injection for the treatment of renal anemia; P-TOL chewable tablets for treating hyperphosphatemia in patients on dialysis; Silodosin for the treatment of dysuria; Mitiglinide for treating Type 2 diabetes mellitus; and RECTABUL AJG511 (Budesonide) for the treatment of ulcerative colitis. Its products under pipeline includes KPS-0373 (Rovatirelin) that is in Phase III clinical trials for treating spinocerebellar ataxia; AJM300 (Carotegrast Methyl), which is in Phase III clinical trials for the treatment of ulcerative colitis; and JR-131, that is in Phase III clinical trials for the treatment of renal anemia. The company is also developing KLH-2109, which is in Phase II clinical trials for treating endometriosis/uterine fibroids; MR13A9 (Difelikefalin) that is in Phase II clinical trials for the treatment of uremic pruritus in dialysis patients; YS110, which is in Phase I/II clinical trials for treating malignant mesothelioma; KDT-3594 that is in Phase I clinical trials for the treatment of Parkinson’s disease; and CCX168 (Avacopan), which is in Phase I clinical trials for the treatment of anti-neutrophil cytoplasmic auto-antibody. In addition, it develops Bedoradrine that is in Phase I and II clinical trials for the treatment of COPD and acute exacerbation of asthma/preterm, as well as provides information solution and construction subcontracting services. Additionally, it offers protein controlled, energy supply, calorie controlled, and elder care foods. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was founded in 1946 and is headquartered in Matsumoto, Japan.